The Hippo Pathway in Cancer: YAP/TAZ and TEAD As Therapeutic Targets in Cancer

Overview

Journal Clin Sci (Lond)

Specialties Biochemistry
General Medicine
Science

Date 2022 Feb 4

PMID 35119068

Authors

Richard Cunningham

Carsten Gram Hansen

Affiliations

Soon will be listed here.

Abstract

Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.

Citing Articles

Deciphering the synergistic role of tyrosyl-tRNA synthetase 1 and yes-associated protein 1: Catalysts of malignant progression in hepatocellular carcinoma.

Zhou L, Zhang X, Zhang C, Wang Y, Zhang J, Wang Y Cytojournal. 2025; 21:66.

PMID: 39917005 PMC: 11801646. DOI: 10.25259/Cytojournal_91_2024.

YAP/TAZ-Hippo pathway mediates the tumorigenesis of various cancers through post-translational modification represented by ubiquitination.

Xu F, Li Z, Guan H, Ma J Cell Death Discov. 2025; 11(1):41.

PMID: 39900917 PMC: 11790847. DOI: 10.1038/s41420-025-02319-w.

Lead exposure promotes NF2-wildtype meningioma cell proliferation through the Merlin-Hippo signaling pathway.

Zhang N, Shen X, Yu Y, Xu L, Wang Z, Zhu J Environ Health Prev Med. 2025; 30:8.

PMID: 39894505 PMC: 11790403. DOI: 10.1265/ehpm.24-00216.

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients.

Schmauch B, Cabeli V, Domingues O, Le Douget J, Hardy A, Belbahri R iScience. 2025; 28(1):111638.

PMID: 39868035 PMC: 11758823. DOI: 10.1016/j.isci.2024.111638.

METTL3-dependent DLG2 inhibits the malignant progression of cervical cancer by inactivating the Hippo/YAP signaling.

Pu M, Xiao X, Lv S, Ran D, Huang Q, Zhou M Hereditas. 2025; 162(1):9.

PMID: 39856747 PMC: 11762078. DOI: 10.1186/s41065-025-00365-z.

References

Bouvier C, Macagno N, Nguyen Q, Loundou A, Jiguet-Jiglaire C, Gentet J . Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma. Oncotarget. 2016; 7(40):64702-64710. PMC: 5323109. DOI: 10.18632/oncotarget.11876. View

Fossdal R, Jonasson F, Kristjansdottir G, Kong A, Stefansson H, Gosh S . A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Hum Mol Genet. 2004; 13(9):975-81. DOI: 10.1093/hmg/ddh106. View

Fang C, Li J, Qi S, Lei Y, Zeng Y, Yu P . An alternatively transcribed variant negatively regulates JAK-STAT signaling. EMBO Rep. 2019; 20(6). PMC: 6549033. DOI: 10.15252/embr.201847227. View

Holden J, Cunningham C . Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors. Cancers (Basel). 2018; 10(3). PMC: 5876656. DOI: 10.3390/cancers10030081. View

Ribeiro P, Josue F, Wepf A, Wehr M, Rinner O, Kelly G . Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol Cell. 2010; 39(4):521-34. DOI: 10.1016/j.molcel.2010.08.002. View

Finicle B, Jayashankar V, Edinger A . Nutrient scavenging in cancer. Nat Rev Cancer. 2018; 18(10):619-633. DOI: 10.1038/s41568-018-0048-x. View

Taniguchi K, Wu L, Grivennikov S, de Jong P, Lian I, Yu F . A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015; 519(7541):57-62. PMC: 4447318. DOI: 10.1038/nature14228. View

McClatchey A, Saotome I, Ramesh V, Gusella J, Jacks T . The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 1997; 11(10):1253-65. DOI: 10.1101/gad.11.10.1253. View

Juan W, Hong W . Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Genes (Basel). 2016; 7(9). PMC: 5042386. DOI: 10.3390/genes7090055. View

10.

Yu F, Luo J, Mo J, Liu G, Kim Y, Meng Z . Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014; 25(6):822-30. PMC: 4075337. DOI: 10.1016/j.ccr.2014.04.017. View

11.

Udan R, Kango-Singh M, Nolo R, Tao C, Halder G . Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol. 2003; 5(10):914-20. DOI: 10.1038/ncb1050. View

12.

Moroishi T, Park H, Qin B, Chen Q, Meng Z, Plouffe S . A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes Dev. 2015; 29(12):1271-84. PMC: 4495398. DOI: 10.1101/gad.262816.115. View

13.

Cosset E, Ilmjarv S, Dutoit V, Elliott K, Von Schalscha T, Camargo M . Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell. 2017; 32(6):856-868.e5. PMC: 5730343. DOI: 10.1016/j.ccell.2017.10.016. View

14.

Chen R, Xie R, Meng Z, Ma S, Guan K . STRIPAK integrates upstream signals to initiate the Hippo kinase cascade. Nat Cell Biol. 2019; 21(12):1565-1577. DOI: 10.1038/s41556-019-0426-y. View

15.

Salcedo Allende M, Zeron-Medina J, Hernandez J, Macarulla T, Balsells J, Merino X . Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. Pancreas. 2017; 46(7):913-920. DOI: 10.1097/MPA.0000000000000867. View

16.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

17.

Regue L, Mou F, Avruch J . G protein-coupled receptors engage the mammalian Hippo pathway through F-actin: F-Actin, assembled in response to Galpha12/13 induced RhoA-GTP, promotes dephosphorylation and activation of the YAP oncogene. Bioessays. 2013; 35(5):430-5. PMC: 4092039. DOI: 10.1002/bies.201200163. View

18.

Cox A, Tsomides A, Yimlamai D, Hwang K, Miesfeld J, Galli G . Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J. 2018; 37(22). PMC: 6236334. DOI: 10.15252/embj.2018100294. View

19.

Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B . Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol. 2015; 17(9):1218-27. PMC: 6186417. DOI: 10.1038/ncb3216. View

20.

Gao J, He L, Zhou L, Jing Y, Wang F, Shi Y . Mechanical force regulation of YAP by F-actin and GPCR revealed by super-resolution imaging. Nanoscale. 2020; 12(4):2703-2714. DOI: 10.1039/c9nr09452k. View